GenesysCapital_Logo
  • About
  • Team
  • Portfolio
  • News
  • LP Login
LP Login

Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

04 June 2024

Fusion: Origin to $2.4 Billion USD

Latest

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

06 December 2024

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

02 December 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

04 November 2024

All Articles

06 December 2024

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Read More
02 December 2024

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Read More
04 November 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Read More
31 October 2024

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

Read More
30 October 2024

Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development

Read More
20 September 2024

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Read More
Load More
1 / 2
About
Team
Portfolio
News
Contact
GenesysCapital_Logo
123 Front Street West, Suite 1503
Toronto ON M5J 2M2
info@genesyscapital.com
Follow us on LinkedIn
Privacy Policy
© 2025 Genesys Capital. All rights reserved.